Epstein Secrets

nglish before returning back to the U.S. and got a job at AT&T who got her management fellowships in the world, at the Sloan School of Management at Massachusetts Institute of Technology. Through her fellowship, Fiorina earned her second master's degree in business administration, and she was placed on a senior management track at AT

huge profits. Gilead, maker of Sovaldi, has profits of around 5o percent. Biogen, Amgen and other biotech firms have profits of around 30 percent. Merck and Pfizer are seeing profits of 18 percent or more. Even if profits were cut by a third or a half, there would be sufficient incentive to assume th

wan arum Adams. ha also puxhax-ff Apponcreas Saatchi The manta mount payable to all digly* doom colectooleundse this bronze:on o 5500 millcn as of Mint& It 2013 Sams to the poky orditiorn and noun oh at the Fern Sturdiestanted kw up so SI 9 maim n the outman ha all your rantshen n a ratan capacry

to sea Figh returns owe tint • lin. stment (Wake Comaration:t Hinted, a PatiOn of the portfolio for at account may ladle canals strategic, limited Merck andante Starr Thoweholteut We may corsoklase al related account statements with the sane adrass it the same envelope, e.g. because they have own

ree in chemistry from Harvard University in 1960 and a Ph.D. degree from the California Institute of Technology in 1964. He was a faculty member of the Massachusetts Institute of Technology from 1963 to 1982. He joined the Department of Chemistry of Harvard University in 1982, where he served as department chairman from 1986 to 1989 an

ufman Fellowship to intern in venture capital. 18 Burt Christensen was the retired head of R&D at Merck PharmaceuticaLs. Whitesides and Roy Vagelos, Merck's former CEO, also served as company directors. 13 EFTA_R1_01521482 EFTA02444567 606-064 The Whitesides Lab Whitesides was unusual as a scien

on University of Cambridge United Kingdom Bence IFIS SpA Banco Santander Prudential Plc Internews Wesfarmers Limited Rio Tinto Plc HEINEKEN Massachusetts Institute of Technology (MIT) Coca-Cola International Nestle SA Columbia Law School Italy Spain United Kingdom USA Australia United Kingdom Netherlands USA USA

iness School Google Inc. USA USA Germany Switzerland USA USA World Economic Forum Annual Meeting EFTA_R1_02105175 EFTA02707407 President, Merck Vaccines MSD USA Julie Louise Gerberding Mikhail Gerchuk Mohammad Abdullah Al Gergawi David R. Gergen Valery Gergiev Natalia Germanova Ola

d a B.A. in Biology and a B.A. in Chemistry at Minnesota State University (Moorhead), and a Ph.D. in Biophysical Chemistry and Molecular Structure at the Massachusetts Institute of Technology (MIT). Isaac’s discoveries led to several publications in top journals, including Science and Cell, and were selected by Science as one of 14 CONTRO

) and Tioga. He was previously on the boards of Intarcia Therapuetics (now currently a Board observer), Sirna Therapeutics (NASDAQ: RNAI, acquired by Merck in 2006 for $1.1 billion), where he served as Chairman; Oriel Therapeutics (acquired by Novartis in 2010), where he served as Executive Chairman, and